3-bromo-5-phenylsulfanyl-pyridine | 284040-68-2

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 3-bromo-5-phenylsulfanyl-pyridine
• 英文别名: 3-Bromo-5-(phenylthio)pyridine；3-bromo-5-phenylsulfanylpyridine
• CAS: 284040-68-2
• 化学式: C₁₁H₈BrNS
• 分子量: 266.161
• InChiKey: JOLLPKXLNVQRNF-UHFFFAOYSA-N

物化性质

• 沸点：
  363.5±27.0 °C(Predicted)
• 密度：
  1.56±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-bromo-5-phenylsulfanyl-pyridine 在 Oxone 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 12.0h， 以59%的产率得到3-(benzenesulfonyl)-5-bromo-pyridine
  参考文献：
  名称：

  MTA-Cooperative PRMT5 Inhibitors

  摘要：

  本发明涉及抑制蛋白精氨酸N-甲基转移酶5（PRMT5）活性的化合物。具体而言，本发明涉及化合物、药物组合物和使用方法，例如使用本发明的化合物和药物组合物治疗癌症的方法。

  公开号：

  US20210078994A1
• 作为产物：
  描述：

  5-溴-3-氟吡啶 、 sodium thiophenolate 以 N,N-二甲基甲酰胺 为溶剂， 以35 %的产率得到3-bromo-5-phenylsulfanyl-pyridine
  参考文献：
  名称：

  [EN] MTA-COOPERATIVE PRMT5 INHIBITORS
  [FR] INHIBITEURS DE PRMT5 COOPÉRATIF À BASE DE MTA

  摘要：

  本发明涉及化合物IIA、IIA-1、IIB、IIB-1、IIC和IIC-1，以及它们的药物组成物和使用方法。这些化合物抑制蛋白质精氨酸甲基转移酶5（PRMT5）的活性，并可用于治疗癌症的方法和药物组成物。

  公开号：

  WO2022192745A1

文献信息

• MTA-Cooperative PRMT5 Inhibitors
  申请人：Mirati Therapeutics, Inc.

  公开号：US20210078994A1

  公开（公告）日：2021-03-18

  The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

  本发明涉及抑制蛋白精氨酸N-甲基转移酶5（PRMT5）活性的化合物。具体而言，本发明涉及化合物、药物组合物和使用方法，例如使用本发明的化合物和药物组合物治疗癌症的方法。
• Homoleptic Zincate‐Promoted Room‐Temperature Halogen–Metal Exchange of Bromopyridines
  作者：Nguyet Trang Thanh Chau、Maxime Meyer、Shinsuke Komagawa、Floris Chevallier、Yves Fort、Masanobu Uchiyama、Florence Mongin、Philippe C. Gros

  DOI：10.1002/chem.201001664

  日期：2010.11.2

  Homoleptic lithium tri‐ and tetraalkyl zincates were reacted with a set of bromopyridines. Efficient and chemoselective bromine–metal exchanges were realized at room temperature with a substoichiometric amount of nBu4ZnLi2⋅TMEDA reagent (1/3 equiv; TMEDA=N,N,N′,N′‐tetramethylethylenediamine). This reactivity contrasted with that of tBu4ZnLi2⋅TMEDA, which was inefficient below one equivalent. DFT calculations

  均三酸锌和四烷基锌酸锂与一组溴吡啶反应。高效和化学选择性溴-金属交换是在室温下以低于化学计算量实现Ñ卜4 ZnLi 2 ⋅TMEDA试剂（1/3当量; TMEDA = Ñ，Ñ，N' ，N'四甲基乙二胺）。该反应性与t Bu 4 ZnLi 2的反应性相反⋅TMEDA，在一个当量以下效率低下。DFT计算使我们能够合理化反应中N⋅⋅⋅Li稳定的聚吡啶基锌盐的形成。使用化学计量的试剂也可以实现二溴吡啶的一锅双功能化。在溴吡啶中直接形成CZn键使我们能够进行有效的Negishi型交叉偶联。
• NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：EP1661904A1

  公开（公告）日：2006-05-31

  A compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, which is useful for a prophylactic and/or therapeutic treatment of a microbial infectious disease. [R1 is hydrogen atom, or a linear C1-6 alkylcarbonyl group; R2 is hydrogen atom, or a C1-6 alkylcarbonyl group; R3 is hydrogen atom, a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C1-6 alkenyl group, a C2-6 alkenylcarbonyl group, a C2-6 alkynyl group, or an Ar-B- group (Ar represents an aryl group, or a heterocyclic group, and B is a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C2-6 alkenyl group, a C2-6 alkenylcarbonyl group, or a C2-6 alkynyl group); R5, R6, R7, and R8 represent hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or an Ar-B'- group (B' is a C1-6 alkyl group, a C2-6 alkenyl group, or a C2-6 alkynyl group); X is oxygen atom, or an -NR4- group (R4 is hydrogen atom, a C1-6 alkyl group, or a C1-6 alkyl group which may be substituted with an Ar group); and R4' is hydrogen atom, or a group represented by the aforementioned formula (a) (R3" and R4" represent hydrogen atom, or a linear or branched C1-6 alkylcarbonyl group)]

  由以下一般式（1）表示的化合物或其药学上可接受的盐，可用于预防和/或治疗微生物感染性疾病。[R1为氢原子，或线性C1-6烷基羰基基团；R2为氢原子，或C1-6烷基羰基基团；R3为氢原子，C1-6烷基基团，C1-6烷基羰基基团，C1-6烯基基团，C2-6烯基羰基基团，C2-6炔基基团，或Ar-B-基团（Ar表示芳基团，或杂环基团，B为C1-6烷基基团，C1-6烷基羰基基团，C2-6烯基基团，C2-6烯基羰基基团，或C2-6炔基基团）；R5、R6、R7和R8表示氢原子，C1-6烷基基团，C2-6烯基基团，C2-6炔基基团，或Ar-B'-基团（B'为C1-6烷基基团，C2-6烯基基团，或C2-6炔基基团）；X为氧原子，或一个-NR4-基团（R4为氢原子，C1-6烷基基团，或C1-6烷基基团，可能被芳基取代）；R4'为氢原子，或由上述式（a）表示的基团（R3"和R4"表示氢原子，或线性或支链状C1-6烷基羰基基团）]
• Nozel azalide and azalactam derivatives and method for producing the same
  申请人：Miura Tomoaki

  公开号：US20070042974A1

  公开（公告）日：2007-02-22

  A compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, which is useful for a prophylactic and/or therapeutic treatment of a microbial infectious disease. [R 1 is hydrogen atom, or a linear C1-6 alkylcarbonyl group; R 2 is hydrogen atom, or a C1-6 alkylcarbonyl group; R 3 is hydrogen atom, a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C1-6 alkenyl group, a C2-6 alkenylcarbonyl group, a C2-6 alkynyl group, or an Ar—B— group (Ar represents an aryl group, or a heterocyclic group, and B is a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C2-6 alkenyl group, a C2-6 alkenylcarbonyl group, or a C2-6 alkynyl group); R 5 , R 6 , R 7 , and R 8 represent hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or an Ar—B′— group (B′ is a C1-6 alkyl group, a C2-6 alkenyl group, or a C2-6 alkynyl group); X is oxygen atom, or an —NR 4 — group (R 4 is hydrogen atom, a C1-6 alkyl group, or a C1-6 alkyl group which may be substituted with an Ar group); and R 4′ is hydrogen atom, or a group represented by the aforementioned formula (a) (R 3″ and R 4″ represent hydrogen atom, or a linear or branched C1-6 alkylcarbonyl group)]

  下列通式（1）所代表的化合物或其药学上可接受的盐，可用于预防和/或治疗微生物感染性疾病。[其中R1为氢原子或线性C1-6烷基羰基基团；R2为氢原子或C1-6烷基羰基基团；R3为氢原子、C1-6烷基、C1-6烷基羰基基团、C1-6烯基、C2-6烯基羰基基团、C2-6炔基或Ar-B-基团（Ar代表芳基或杂环基，B为C1-6烷基、C1-6烷基羰基基团、C2-6烯基、C2-6烯基羰基基团或C2-6炔基）；R5、R6、R7和R8代表氢原子、C1-6烷基、C2-6烯基、C2-6炔基或Ar-B′-基团（B′为C1-6烷基、C2-6烯基或C2-6炔基）；X为氧原子或-NR4-基团（R4为氢原子、C1-6烷基或可被芳基取代的C1-6烷基）；R4′为氢原子或上述通式（a）所代表的基团（R3″和R4″代表氢原子或线性或支链状C1-6烷基羰基基团）]
• Azalide and azalactam derivatives and method for producing the same
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：US07365174B2

  公开（公告）日：2008-04-29

  Compounds represented by the general formula (1) or pharmaceutically acceptable salts thereof, effective in the prevention and/or treatment of infections with microbes: (1) (a) wherein R1 is hydrogen or straight-chain C1-6 alkylcarbonyl; R2 is hydrogen or C1-6 alkylcarbonyl; R3 is hydrogen, C1-6 alkyl, C1-6 alkylcarbonyl, C1-6 alkenyl, C2-6 alkenylcarbonyl, C2-6 alkynyl, or an Ar—B— group (wherein Ar is aryl or a heterocyclic group; and B is C1-6 alkyl, C1-6 alkylcarbonyl, C2-6 alkenyl, C2-6 alkenylcarbonyl, or C2-6 alkynyl); R5, R6, R7 and R8 are each hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or an Ar—B′— group (wherein B′ is C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl); X is oxygen or —NR4— (wherein R4 is hydrogen, C1-6 alkyl or C1-6 alkyl which may be substituted with Ar); and R4′ is hydrogen or a group represented by the general formula (a) (wherein R3″ and R4″ are each hydrogen or straight-chain or branched C1-6 alkylcarbonyl)

  通式（1）或其药学上可接受的盐，对微生物感染的预防和/或治疗有效的化合物：（1）（a），其中R1是氢或直链C1-6烷基羰基；R2是氢或C1-6烷基羰基；R3是氢，C1-6烷基，C1-6烷基羰基，C1-6烯基，C2-6烯基羰基，C2-6炔基或Ar-B-基团（其中Ar是芳基或杂环基团；B是C1-6烷基，C1-6烷基羰基，C2-6烯基，C2-6烯基羰基或C2-6炔基）；R5、R6、R7和R8分别是氢，C1-6烷基，C2-6烯基，C2-6炔基或Ar-B′-基团（其中B′是C1-6烷基，C2-6烯基或C2-6炔基）；X是氧或-NR4-（其中R4是氢，C1-6烷基或C1-6烷基，可以用Ar取代）；R4'是氢或通式（a）所表示的基团（其中R3"和R4"分别是氢或直链或支链C1-6烷基羰基）。